Euronext Paris

Patient Centricity, AI-Powered Insights and Diversity in Clinical Trials Among Key Topics at Medidata NEXT London

Retrieved on: 
Wednesday, May 18, 2022 - 9:00am

NEXT London will include keynote presentations, interactive breakout sessions, patient advocate and customer success stories, product demonstrations and networking opportunities.

Key Points: 
  • NEXT London will include keynote presentations, interactive breakout sessions, patient advocate and customer success stories, product demonstrations and networking opportunities.
  • Attendance to NEXT London and NEXT Basel is free for customers, partners and qualified members of the life sciences community.
  • Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes.
  • Dassault Systmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries.

Poxel Announces PXL065 and PXL770 Granted Orphan Drug Designation from the U.S. FDA for X-Linked Adrenoleukodystrophy

Retrieved on: 
Tuesday, May 17, 2022 - 4:45pm

Poxel CEO, Thomas Kuhn, commented: The award of Orphan Drug Designation to both PXL065 and PXL770 by the FDA is an additional regulatory milestone for the development of these potential medicines in X-linked adrenoleukodystrophy, for which there is currently no approved therapy.

Key Points: 
  • Poxel CEO, Thomas Kuhn, commented: The award of Orphan Drug Designation to both PXL065 and PXL770 by the FDA is an additional regulatory milestone for the development of these potential medicines in X-linked adrenoleukodystrophy, for which there is currently no approved therapy.
  • We remain excited to pursue treatments for ALD as this represents an area with very high unmet medical need.
  • For the rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the company intends to initiate Phase 2a proof of concept studies with PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN).
  • 1 For more information on Orphan Drug Designation, see : https://www.fda.gov/industry/developing-products-rare-diseases-condition...
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005860/en/

Banks Shift to Eco-friendly Solutions Supported by Innovative Thales Cards, Certified Sustainable by Mastercard

Retrieved on: 
Wednesday, May 18, 2022 - 7:00am

With environmental challenges now a growing, global concern, Thales, the leader in high tech security, has developed solutions for a greener world, recently certified by Mastercards Sustainable Card Program.

Key Points: 
  • With environmental challenges now a growing, global concern, Thales, the leader in high tech security, has developed solutions for a greener world, recently certified by Mastercards Sustainable Card Program.
  • To date, Thales has deployed 30 million eco-friendly payment cards for banks and card issuers that address consumer concerns without compromising the user experience.
  • View the full release here: https://www.businesswire.com/news/home/20220517005012/en/
    All eco-friendly cards offered by Thales are made with innovative and sustainable components.
  • This certification demonstrates that Thales solutions have an environmental advantage that is meaningful, verified and sustainable.

Ipsos appoints Mark Polyak as President of Analytics, Ipsos North America

Retrieved on: 
Wednesday, May 18, 2022 - 7:25pm

NEW YORK, May 18, 2022 /PRNewswire/ -- Ipsos, one of the world's leading research and insights organizations, today announced Mark Polyak's appointment as President of Analytics for Ipsos in North America. As President, Polyak will play a critical role in the strategic growth of Ipsos' business and the integration of multisource, real-time, data-driven and actionable insights into its core operations.

Key Points: 
  • NEW YORK, May 18, 2022 /PRNewswire/ -- Ipsos, one of the world's leading research and insights organizations, today announced Mark Polyak's appointment as President of Analytics for Ipsos in North America.
  • In his new position, he will advise key clients, contribute thought leadership on Ipsos' innovative approach to "in-the-moment" intelligence, and accelerate Ipsos' digital analytics transformation.
  • "Mark has brought considerable knowledge, data-driven product innovation and expertise to Public Affairs," said Lorenzo Larini, CEO, Ipsos North America.
  • As part of his new role, which starts June 1, Polyak will join the North America Leadership Team.

Legrand Introduces Nexpand, The New Configure-to-Order Cabinet Platform For The Data Center Market

Retrieved on: 
Wednesday, May 18, 2022 - 12:05pm

WEST HARTFORD, Conn., May 18, 2022  /PRNewswire-PRWeb/ -- Customer Input Makes New Platform Design Ideal for Supporting 5G, AI, IoT, and Other Emerging Technologies

Key Points: 
  • Legrand, the global specialist in electrical and digital building infrastructures, today unveiled Nexpand, its new data center cabinet platform.
  • The new platform is flexible, sturdy, and secure for housing data center devices.
  • "Legrand's innovations are predicated on delivering solutions to our customers in the most efficient manner possible," said Saman Berookhim, Product Manager, Legrand.
  • "The Nexpand cabinet honors this philosophy by offering a single, configure-to-order platform that will enable our customers to easily scale as needed in a robust and configurable manner."

Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022

Retrieved on: 
Tuesday, May 17, 2022 - 1:13pm

Aptorum Group management will be available and conducting online one-on-one meetings with institutional investors through the conference.

Key Points: 
  • Aptorum Group management will be available and conducting online one-on-one meetings with institutional investors through the conference.
  • The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g.
  • This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.
  • Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Thales Signs an Agreement with Sonae Investment Management to Acquire S21sec and Excellium, Reinforcing Its Cybersecurity Activities

Retrieved on: 
Tuesday, May 17, 2022 - 8:26am

Thales (Euronext Paris: HO) announces today the signature of a definitive agreement with Sonae Investment Management to acquire two of European leading cybersecurity companies, S21sec and Excellium, gathered under the holding company Maxive Cybersecurity.

Key Points: 
  • Thales (Euronext Paris: HO) announces today the signature of a definitive agreement with Sonae Investment Management to acquire two of European leading cybersecurity companies, S21sec and Excellium, gathered under the holding company Maxive Cybersecurity.
  • This acquisition will complement Thales cybersecurity portfolio, strengthening its incident detection and response services (Security Operations Centre SOC) as well as consulting, audit and integration services.
  • With 546 employees, S21sec and Excellium businesses together generated 59 million euros in sales in 2021.
  • We are delighted to welcome the S21sec and Excellium expert teams as part of our fast-growing cybersecurity teams.

Inventiva reports 2022 First Quarter Financial Information and provides clinical development update

Retrieved on: 
Monday, May 16, 2022 - 9:00pm

R&D expenses for the first quarter, mainly driven by the development of lanifibranor in NASH, were up 74% compared to the first quarter of 2022.

Key Points: 
  • R&D expenses for the first quarter, mainly driven by the development of lanifibranor in NASH, were up 74% compared to the first quarter of 2022.
  • This significant increase in R&D expenses is driven by the costs associated with the NATiV3 Phase III clinical trial with lanifibranor in NASH.
  • Net cash used in investing activities for the first quarter of 2022 amounted to 0.1 million, compared to 1.1 million in the first quarter of 2021.
  • No net cash from financing activities was generated over the first quarter of 2022, same as for the first quarter of 2021.

Verimatrix Anti-Piracy and Threat Defense Experts To Highlight Latest Innovations at CABSAT and TT CS

Retrieved on: 
Monday, May 16, 2022 - 4:45pm

Held at the Sheraton Brussels Airport Hotel, the event features two Verimatrix speakers.

Key Points: 
  • Held at the Sheraton Brussels Airport Hotel, the event features two Verimatrix speakers.
  • Nicole Lua, sales director, is scheduled to serve as moderator for a Security By Design roundtable at 1:35 p.m. on May 17.
  • Verimatrix executives will be on hand in Stand B6-32 at the Dubai World Trade Center, where the latest Verimatrix Secure Delivery Platform and Streamkeeper innovations will be highlighted.
  • Verimatrix executives are available at each event to discuss the industrys latest challenges as well as innovations.

MICT’s Merger Target Announces its Q1 2022 Results

Retrieved on: 
Monday, May 16, 2022 - 2:00pm

Earlier today, Tingo announced its results for the quarter ended March 31st, 2022 and filed its Quarterly Report on Form 10-Q.

Key Points: 
  • Earlier today, Tingo announced its results for the quarter ended March 31st, 2022 and filed its Quarterly Report on Form 10-Q.
  • With regard to the status of the merger, due diligence work is underway, and significant progress is being made on the transaction process.
  • In connection with the proposed Merger, the Company will file a proxy statement on Schedule 14A with the SEC.
  • This press release does not constitute a solicitation of a proxy from any stockholder with respect to the proposed Merger.